Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges. In an analysis published in Med Device Online, we explored how medtech companies should approach the reimbursement pathway for these devices when seeking to enter the German market.
CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...